SCHEMBL6764633

SCHEMBL6764633

Cc1cccc(C(=O)Nc2ccc(S(=O)(=O)CC(C)(O)C(=O)NO)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
TP53 P04637 2/20 0.52
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
GPR17 Q13304 3/20 0.50
FFAR1 O14842 1/20 0.50
GLA P06280 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
KCNK3 O14649 4/20 0.49
KCNK9 Q9NPC2 3/20 0.49
KCNH2 Q12809 1/20 0.49
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2D6 P10635 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NT5E P21589 1/20 0.48
HDAC8 Q9BY41 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768091 0.88 MAPT (0.53) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL6768704 0.88 CYP2C19 (0.50) NPC1RAB9AMEN1KMT2AGPR17
SCHEMBL6764893 0.88 PTGS1 (0.50) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL6764639 0.88 PRMT1 (0.55) MEN1KMT2ALMNAMAPTCYP3A4
SCHEMBL6764878 0.86 TP53 (0.56) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL6769180 0.86 GHSR (0.53) NPC1RAB9AMEN1KMT2ACYP3A4
SCHEMBL6768589 0.83 AR (0.46) MAPTCYP3A4CYP2C9CYP2C19CYP2D6
SCHEMBL6764641 0.81 MAPT (0.54) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL6769208 0.80 ALDH1A1 (0.52) MEN1KMT2ALMNAMAPTCYP3A4
SCHEMBL6764678 0.78 ENPP1 (0.53) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 NPC1 2284/4885RAB9A 3300/4885TP53 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.